Europe Allergy Immunotherapy Market Size & Outlook
Europe allergy immunotherapy market, 2016-2027 (US$M)
Related Markets
Europe allergy immunotherapy market highlights
- The Europe allergy immunotherapy market generated a revenue of USD 1,105.9 million in 2019.
- The market is expected to grow at a CAGR of 8.4% from 2020 to 2027.
- In terms of segment, subcutaneous immunotherapy was the largest revenue generating treatment type in 2019.
- Sublingual immunotherapy is the most lucrative treatment type segment registering the fastest growth during the forecast period.
- Country-wise, France is expected to register the highest CAGR from 2020 to 2027.
Europe data book summary
| Market revenue in 2019 | USD 1,105.9 million |
| Market revenue in 2027 | USD 2,111.5 million |
| Growth rate | 8.4% (CAGR from 2019 to 2027) |
| Largest segment | Subcutaneous immunotherapy |
| Fastest growing segment | Sublingual immunotherapy |
| Historical data covered | 2016 - 2018 |
| Base year for estimation | 2019 |
| Forecast period covered | 2020 - 2027 |
| Quantitative units | Revenue in USD million |
| Market segmentation | Subcutaneous immunotherapy, Sublingual immunotherapy |
| Key market players worldwide | Merck KGaA, Allergy Therapeutics PLC, DBV Technologies SA ADR, ASIT biotech, Circassia, Mylan, DMK Pharmaceuticals Corp, Alk-Abello A/S Class B, Desentum, HAL Allergy Group, HollisterStier Allergy, Stallergenes Greer |
Other key industry trends
- In terms of revenue, Europe region accounted for 69.1% of the global allergy immunotherapy market in 2019.
- Globally, Europe is projected to lead the regional market in terms of revenue in 2027.
- Asia Pacific is the fastest growing regional market and is projected to reach USD 255.9 million by 2027.
No credit card required*
Horizon in a snapshot
- 30K+ Global Market Reports
- 120K+ Country Reports
- 1.2M+ Market Statistics
- 200K+ Company Profiles
- Industry insights and more
Allergy Immunotherapy Market Scope
Allergy Immunotherapy Market Companies
| Name | Profile | # Employees | HQ | Website |
|---|
Europe allergy immunotherapy market outlook
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to allergy immunotherapy market will help companies and investors design strategic landscapes.
Subcutaneous immunotherapy was the largest segment with a revenue share of 58.49% in 2019. Horizon Databook has segmented the Europe allergy immunotherapy market based on subcutaneous immunotherapy, sublingual immunotherapy covering the revenue growth of each sub-segment from 2016 to 2027.
Allergy is one of the most common chronic disorders that affects European population. Nearly 20% of allergic patients struggle daily fearing a possible attack of anaphylactic shock, asthma, even death in extreme cases.
At present, more than 150 million Europeans suffer from allergic disorders and it is expected that more than 50% of the population of Europe would be affected by at least one form of allergy by 2025. This alarming rate of increase is fueled by industrialization, urbanization, climate change, and pollution in the region.
The rise in prevalence often creates burden on productivity and daily living of people. According to the European Academy of Allergy and Clinical Immunology (EAACI), allergic rhinitis and asthma alone result in 100 million missed school days, and lost workdays annually.
Reasons to subscribe to Europe allergy immunotherapy market databook:
-
Access to comprehensive data: Horizon Databook provides over 1 million market statistics and 20,000+ reports, offering extensive coverage across various industries and regions.
-
Informed decision making: Subscribers gain insights into market trends, customer preferences, and competitor strategies, empowering informed business decisions.
-
Cost-Effective solution: It's recognized as the world's most cost-effective market research database, offering high ROI through its vast repository of data and reports.
-
Customizable reports: Tailored reports and analytics allow companies to drill down into specific markets, demographics, or product segments, adapting to unique business needs.
-
Strategic advantage: By staying updated with the latest market intelligence, companies can stay ahead of competitors, anticipate industry shifts, and capitalize on emerging opportunities.
Target buyers of Europe allergy immunotherapy market databook
-
Our clientele includes a mix of allergy immunotherapy market companies, investment firms, advisory firms & academic institutions.
-
30% of our revenue is generated working with investment firms and helping them identify viable opportunity areas.
-
Approximately 65% of our revenue is generated working with competitive intelligence & market intelligence teams of market participants (manufacturers, service providers, etc.).
-
The rest of the revenue is generated working with academic and research not-for-profit institutes. We do our bit of pro-bono by working with these institutions at subsidized rates.
Horizon Databook provides a detailed overview of continent-level data and insights on the Europe allergy immunotherapy market, including forecasts for subscribers. This continent databook contains high-level insights into Europe allergy immunotherapy market from 2016 to 2027, including revenue numbers, major trends, and company profiles.
Partial client list
Europe allergy immunotherapy market size, by country, 2016-2027 (US$M)
Europe Allergy Immunotherapy Market Share, 2019 & 2027 (US$M)
Related regional statistics
No records
No related regions found.
Sign up - it's easy, and free!
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account
- 30K+ Global Market Reports
- 120K+ Country Reports
- 1.2M+ Market Statistics
- 200K+ Company Profiles
- Industry insights and more
